Kawasaki disease
Conditions
Interventions
Intravenous immunoglobulin (2g/kg) over 24 h with aspirin (30mg/kg/day). The dosage of aspirin can be reduced to 5 mg/kg/day after resolution of fever.
Intravenous immunoglobulin (2g/kg) over 24 h plu
Sponsors
Nagoya University Graduate School of Medicine, Department of Pediatrics
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Severe Kawasaki disease patients of risk score 4 points or more. 2. Written informed consent is obtained from patients or their parents. 3. Streptococcus, Epstain-Bar virus, adenovirus, or yersinia infection, or measles, or Stevens-Johnson syndrome is ruled out.
Exclusion criteria
Exclusion criteria: 1. Patients with past histories of Kawasaki disease 2. Patients diagnosed as Kawasaki disease on the ninth day of illness or later. 3. Kawasaki disease patients with coronary artery lesions before treatment 4. Kawasaki disease patients with defervescence before treatment 5. Patients given steroids within 28 days before treatment 6. Patients given IVIG within 180 days before treatment 7. Patients with severe underlining diseases 8. Patients with bacterial infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of coronary artery lesions within 4 weeks after primary treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of coronary artery lesions at 4 weeks after primary treatment, Z score of coronary artery diameters, incidence of resistance to primary treatment or relapse, duration of fever after primary treatment, serum concentrations of C-reactive protein at 1 week and 2 weeks after primary treatment, and incidence of adverse events | — |
Countries
Japan
Contacts
Public ContactTaichi Kato
Nagoya University Graduate School of Medicine Department of Pediatrics
Outcome results
None listed